Selected Quarterly Financial Data (Unaudited) (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 14, 2017 |
Aug. 31, 2017 |
Dec. 31, 2017 |
Sep. 30, 2017 |
Jun. 30, 2017 |
Mar. 31, 2017 |
Dec. 31, 2016 |
Sep. 30, 2016 |
Jun. 30, 2016 |
Mar. 31, 2016 |
Dec. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
|
| Quarterly Financial Data [Abstract] | |||||||||||||
| License and other revenue | $ 25,000,000 | $ 25,000,000 | $ 0 | $ 25,000,000 | $ 0 | $ 0 | $ 25,000,000 | $ 0 | $ 0 | ||||
| Product revenue, net | 1,911,000 | 0 | 0 | 0 | 1,910,403 | 0 | 0 | ||||||
| Sales force revenue | 278,000 | 0 | 0 | 0 | 278,165 | 0 | 0 | ||||||
| Grant revenue | 45,000 | 38,000 | 158,000 | 384,000 | 624,569 | 1,152,987 | 0 | ||||||
| Cost of product sales | 636,000 | 0 | 0 | 0 | 635,648 | 0 | 0 | ||||||
| Research and development | 1,961,000 | 965,000 | 494,000 | 953,000 | $ 773,000 | $ 4,582,000 | $ 2,502,000 | $ 2,293,000 | 4,372,578 | 10,149,879 | 6,587,183 | ||
| General and administrative | 3,021,000 | 2,152,000 | 1,439,000 | 1,330,000 | 1,095,000 | 1,703,000 | 1,636,000 | 2,649,000 | 7,941,584 | 7,083,155 | 4,422,764 | ||
| Sales and marketing | 973,000 | 0 | 0 | 0 | 973,345 | 0 | 0 | ||||||
| Change in fair value of warrant liability, unit purchase option liability and investor rights obligation | (28,000) | 0 | 2,000 | (4,000) | 130,000 | (101,000) | 91,000 | (47,000) | (29,624) | 72,625 | 1,313,049 | ||
| Interest expense, net | 31,000 | 29,000 | (26,000) | (58,000) | (83,000) | (104,000) | (127,000) | (151,000) | (24,016) | (464,181) | (793,205) | ||
| Net income (loss) | $ (3,091,000) | $ 18,721,000 | $ (1,799,000) | $ (1,961,000) | $ (1,639,000) | $ (6,169,000) | $ (3,524,000) | $ (5,140,000) | $ 11,869,823 | $ (16,471,603) | $ (10,490,103) | ||
| Net income (loss) per share of common stock, basic (in dollars per share) | $ (0.11) | $ 0.52 | $ (0.14) | $ (0.19) | $ 0.42 | $ (1.87) | $ (4.71) | ||||||
| Net income (loss) per share of common stock, diluted (in dollars per share) | $ (0.11) | $ 0.52 | $ (0.14) | $ (0.19) | $ 0.42 | $ (1.87) | $ (4.71) | ||||||
| Net loss per share of common stock, basic and diluted (in dollars per share) | $ (0.18) | $ (0.70) | $ (0.41) | $ (0.59) | |||||||||
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability and investor rights obligation. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total costs related to goods produced and sold during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net amount of nonoperating interest income (expense). No definition available.
|
| X | ||||||||||
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|